Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry

Purpose The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LI...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2023-01, Vol.197 (2), p.377-385
Main Authors: Kada Mohammed, Samia, Dabakuyo Yonli, Tienhan Sandrine, Desmoulins, Isabelle, Manguem Kamga, Ariane, Jankowski, Clémentine, Padeano, Marie-Martine, Loustalot, Catherine, Costaz, Hélène, Causeret, Sylvain, Peignaux, Karine, Rouffiac, Magali, Coutant, Charles, Arnould, Laurent, Ladoire, Sylvain
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Cancer research
Carcinoma
Clinical Trial
Comparative analysis
Diagnosis
Ecology, environment
ErbB-2 protein
Estrogen
Estrogen receptors
Health
Health aspects
Invasiveness
Life Sciences
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Metastasis
Oncology
Oncology, Experimental
Patients
Population studies
Population-based studies
Prognosis
Statistical analysis
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC. Methods We designed a retrospective study using data from the specialized Côte d’Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied. Results Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS. Conclusion LIR after CIS does not appear to impact per se on survival of IBC.
ISSN:0167-6806
1573-7217
1573-7217
DOI:10.1007/s10549-022-06807-w